Carbon dots as dual inhibitors of tau and amyloid-beta aggregation for the treatment of Alzheimer's disease
Acta Biomaterialia · 2024
DOI: 10.1016/j.actbio.2024.06.001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Biomaterialia, 2024. Verfasst von Wei Zhang und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, University of Miami, Coral Gables, FL 33146, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Amyloid beta-Peptides, Carbon, tau Proteins. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, National Institutes of Health, University of Miami.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer's disease (AD) is the most common form of senile dementia, presenting a significant challenge for the development of effective treatments. AD is characterized by extracellular amyloid plaques and intraneuronal neurofibrillary tangles. Therefore, targeting both hallmarks through inhibition of amyloid beta (Aβ) and tau aggregation presents a promising approach for drug development. Carbon dots (CD), with their high biocompatibility, minimal cytotoxicity, and blood-brain barrier (BBB) permeability, have emerged as promising drug nanocarriers. Congo red, an azo dye, has gathered significant attention for inhibiting amyloid-beta and tau aggregation. However, Congo red's inability to cross the BBB limits its potential to be used as a drug candidate for central nervous system (CNS) diseases. Furthermore, current studies only focus on using Congo red to target single disease hallmarks, without investigating dual inhibition capabilities. In this study, we synthesized Congo red-derived CD (CRCD) by using Congo red and citric acid as precursors, resulting in three variants, CRCD1, CRCD2 and CRCD3, based on different mass ratios of precursors. CRCD2 and CRCD3 exhibited sustained low cytotoxicity, and CRCD3 demonstrated the ability to traverse the BBB in a zebrafish model. Moreover, thioflavin T (ThT) aggregation assays and AFM imaging revealed CRCD as potent inhibitors against both tau and Aβ aggregation. Notably, CRCD1 emerged as the most robust inhibitor, displaying IC50 values of 0.2 ± 0.1 and 2.1 ± 0.5 µg/mL against tau and Aβ aggregation, respectively. Our findings underscore the dual inhibitory role of CRCD against tau and Aβ aggregation, showcasing effective BBB penetration and positioning CRCD as potential nanodrugs and nanocarriers for the CNS. Hence, CRCD-based compounds represent a promising candidate in the realm of multi-functional AD therapeutics, offering an innovative formulation component for future developments in this area. STATEMENT OF SIGNIFICANCE: This article reports Congo red-derived carbon dots (CRCD) as dual inhibitors of tau and amyloid-beta (Aβ) aggregation for the treatment of Alzheimer's disease (AD). The CRCD are biocompatible and show strong fluorescence, high stability, the ability to cross the blood-brain barrier, and the function of addressing two major pathological features of AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, University of Miami, Coral Gables, FL 33146, USA.
- Department of Biological Sciences, Rensselaer Polytechnic Institute, NY 12180, USA.
- Department of Chemistry, University of Miami, Coral Gables, FL 33146, USA; Department of Biological Sciences, Florida International University, Miami, FL 33199, USA.
- Department of Applied Science and Technology, Politecnico di Torino, Italy; Center for Sustainable Future Technologies (CSFT), Istituto Italiano di Technologia (IIT), Via Livorno 60, 10144 Turin, Italy.
- Department of Biochemistry, Weill Cornell Medicine, 1300 York Avenue, New York, NY 10065, USA.
- Department of Applied Science and Technology, Politecnico di Torino, Italy.
Förderung
- NIA NIH HHS
- National Institutes of Health
- University of Miami
- Rensselaer Polytechnic Institute
- Florida Department of Health
Zitieren
APA
Zhang, W., Smith, N., Zhou, Y., McGee, C. M., Bartoli, M., Fu, S., Chen, J., Domena, J. B., Joji, A., Burr, H., Lv, G., Cilingir, E. K., Bedendo, S., Claure, M. L., Tagliaferro, A., Eliezer, D., Veliz, E. A., Zhang, F., Wang, C., & Leblanc, R. M. (2024). Carbon dots as dual inhibitors of tau and amyloid-beta aggregation for the treatment of Alzheimer's disease. Acta Biomaterialia. https://doi.org/10.1016/j.actbio.2024.06.001
Vancouver
Zhang W, Smith N, Zhou Y, McGee CM, Bartoli M, Fu S, et al. Carbon dots as dual inhibitors of tau and amyloid-beta aggregation for the treatment of Alzheimer's disease. Acta Biomaterialia. 2024. doi:10.1016/j.actbio.2024.06.001
BibTeX
@article{Zhang2024,
author = {Zhang, Wei and Smith, Nathan and Zhou, Yiqun and McGee, Caitlin M and Bartoli, Mattia and Fu, Shiwei and Chen, Jiuyan and Domena, Justin B and Joji, Annu and Burr, Hannah and Lv, Guohua and Cilingir, Emel K and Bedendo, Susanna and Claure, Matteo L and Tagliaferro, Alberto and Eliezer, David and Veliz, Eduardo A and Zhang, Fuwu and Wang, Chunyu and Leblanc, Roger M},
title = {Carbon dots as dual inhibitors of tau and amyloid-beta aggregation for the treatment of Alzheimer's disease},
journal = {Acta Biomaterialia},
year = {2024},
doi = {10.1016/j.actbio.2024.06.001}
}
EUVIMED